TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20637149
Drug: Diazepam (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (maintenance dose 0.5‐1 mg/kg per hour)
Study: 12053548
Drug: Steroids for
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids for diffuse proliferative extracapillary forms or moderately severe NIgA with normal renal function
Study: 25427598
Drug: Midazolam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.1 mg/kg IV)
Study: 24756515
Drug: Diazepam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.2 mg/kg IV)
Study: 26181087
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 micrograms every 3 hours for up to six doses)
Study: 26181087
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol (400 micrograms every 3 hours for up to six doses)
Study: 26181087
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol and Buccal misoprostol
Study: 18449422
Drug: DDAVP administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP administration
Study: 14517521
Drug: i.v.GG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v.GG plus corticosteroids (G+S group)
Study: 14517521
Drug: i.v.GG alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v.GG alone (G group)
Study: 3277558
Drug: Psyllium hydrophilic
Normalized name: PSYLLIUM HYDROPHILIC MUCILLOID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium hydrophilic mucilloid (3.4 g, three doses per day)
Study: 23158515
Drug: scGOS/lcFOS (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: scGOS/lcFOS (0.8 g/100 ml)
Study: 20850959
Drug: Indacaterol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 300 μg once daily (PM)
Study: 20850959
Drug: Indacaterol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 300 μg once daily (AM)
Study: 21660300
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 μg twice daily
Study: 16258919
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise 3 times weekly for 4 months
Study: 12406669
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (12 micro g)
Study: 12406669
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (200 micro g)
Study: 12406669
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol (50 micro g)
Study: 11247067
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg administered daily for 12 to 24 weeks
Study: 7972972
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (8 mg four times daily)
Study: 21554710
Drug: Flaxseed supplementation
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed supplementation (40 g daily for 12 weeks)
Study: 21554710
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran supplementation (40 g daily for 12 weeks)
Study: 12839281
Drug: DTwPHib vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTwPHib vaccine
Study: 9358531
Drug: Intraperitoneal clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal clindamycin (20 mg/kg body weight, four times per day)
Study: 9358531
Drug: Oral clindamycin
Normalized name: clindamycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clindamycin (20 mg/kg body weight, three times per day)
Study: 29530072
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) alone (S1)
Study: 29530072
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CT) with extracorporeal hemoperfusion therapy (HCT) (S2)
Study: 25304851
Drug: 1% cidofovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% cidofovir (gel, 10 g tube, applied for 6 weeks)
Study: 25304851
Drug: 5% imiquimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% imiquimod (250 mg sachet, self-applied three times a week for a maximum of 24 weeks)
Study: 17852477
Drug: Blueberry nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry nutritional supplement
Study: 17852477
Drug: Blueberry nutritional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry nutritional supplement and Placebo
Study: 15463813
Drug: TLC C‐53
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC C‐53 (prostaglandin E(1) associated with egg phosphatidylcholine liposomes) at doses of 0.15-1.8 microg/kg by 4 x 1-h infusions
Study: 30850837
Drug: Total protein
Normalized name: Total Protein Reagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total protein intake (0.90 g · kg‐1 · d‐1)
Study: 28662466
Drug: Performance-contingent reward
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performance-contingent reward with informationally administered reward
Study: 16443257
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus phenprocoumon
Study: 11434052
Drug: LMWH (Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH (Low Molecular Weight Heparin)
Study: 11434052
Drug: Proven therapies
Normalized name: Provenge
DrugBank: Sipuleucel-T (DB06688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proven therapies
Study: 8980774
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delavirdine mesylate (400 mg)
Study: 8980774
Drug: Didanosine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (125 to 200 mg buffered tablets)
Study: 8980774
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of delavirdine and didanosine
Study: 8356961
Drug: Standard Schwarz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Schwarz vaccine
Study: 8356961
Drug: High-titer Edmonston-Zagreb
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer Edmonston-Zagreb vaccine
Study: 8356961
Drug: High-titer Schwarz
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer Schwarz vaccine
Study: 3318426
Drug: Nabumetone, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone, 1,000 mg at bedtime
Study: 22290270
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron polymaltose (500 mg single dose)
Study: 22290270
Drug: PO ferrous
Normalized name: Ferrous Fumarate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO ferrous sulfate (210 mg elemental iron daily, continuously)
Study: 16084152
Drug: full-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: full-dose tenecteplase alone
Study: 12360587
Drug: Histochrome 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histochrome 100 mg administered 10 min before and 1 hour after thrombolytic therapy (group 1A)
Study: 12360587
Drug: Histochrome 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histochrome 100 mg on disease day 1 followed by 100 mg/day for 10 days (group 1B)
Study: 7756063
Drug: Intravenous isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isosorbide dinitrate
Study: 24706022
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection (PAI) using ropivacaine, epinephrine, ketorolac, and morphine
Study: 18707755
Drug: Normoglycemic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoglycemic treatment (4.72 mmol/L)
Study: 18707755
Drug: Moderate hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hyperglycemia (11.1 mmol/L)
Study: 18707755
Drug: High-grade hyperglycemia
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-grade hyperglycemia (16.7 mmol/L)
Study: 16145306
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of oral estradiol combined with 25 microg of gestodene (oE2 + G, n = 33)
Study: 16145306
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of oral estradiol (oE2, n = 37)
Study: 16145306
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg of transdermal 17ss-estradiol (tE2, n = 33)
Study: 10517313
Drug: IFN monotherapy
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN monotherapy (3 x 4.5 million units IFN‐alpha 2a per week)
Study: 10517313
Drug: IFN and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN and N‐acetylcysteine (NAC) 1.800 mg/day) plus sodium selenite (400 microg/day) supplementation
Study: 10517313
Drug: IFN, N‐acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN, N‐acetylcysteine (NAC) 1.800 mg/day, sodium selenite (400 microg/day) plus vitamin E (544 IU/day)
Study: 8834093
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml 0.9% saline)
Study: 18164501
Drug: Cortisol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (50 mg)
Study: 19834961
Drug: Casopitant 50
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 50 mg plus ondansetron/dexamethasone
Study: 19834961
Drug: Casopitant 100
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 100 mg plus ondansetron/dexamethasone
Study: 19834961
Drug: Casopitant 150
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 150 mg plus ondansetron/dexamethasone
Study: 19834961
Drug: Single-dose casopitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose casopitant 150 mg plus ondansetron/dexamethasone
Study: 19834961
Drug: Once-daily ondansetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily ondansetron plus casopitant
Study: 15572269
Drug: Amantadine (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100-300 mg/day)
Study: 12165818
Drug: Randomized acid
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized acid infusion test
Study: 14723389
Drug: Anabolic-androgenic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic-androgenic steroids
Study: 7496846
Drug: Nonusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers of anabolic-androgenic steroids
Study: 15321287
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (5 mg)
Study: 19859698
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (5 mg)
Study: 26108265
Drug: MA 60
Normalized name: Drizalma 60 MG Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 60 mg/kg/d IM and oral placebo
Study: 26108265
Drug: MA 30
Normalized name: Lasma 300 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 30 mg/kg/d IM and oral cimetidine 1200 mg/d
Study: 26108265
Drug: MA 30
Normalized name: Lasma 300 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 30 mg/kg/d IM and oral placebo
Study: 15364318
Drug: No glycoprotein
Normalized name: Alpha>2< neuramino glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: No glycoprotein (GP) IIb/IIIa inhibitor
Study: 15364318
Drug: GP IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa inhibitor bolus followed by maintenance infusion
Study: 12373267
Drug: CAMP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAMP treatment
Study: 8194619
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin (hCG) with GnRH agonist
Study: 22577959
Drug: Platform-switched implant
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched implant (test)
Study: 22577959
Drug: Platform-matched implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-matched implant (control)
Study: 22248747
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (IGC) to maintain glucose level between 6.1 mmol/L and 8.3 mmol/L
Study: 18803000
Drug: AMT 25
Normalized name: luspatercept-aamt 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMT 25 mg
Study: 18803000
Drug: AMT 50
Normalized name: Amtagvi
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMT 50 mg
Study: 16040472
Drug: Combined manipulation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined manipulation, exercise, and physician consultation (combination group)
Study: 16040472
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (combination and consultation)
Study: 12015789
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg gliclazide MR tablet
Study: 12015789
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg gliclazide MR tablet under fasted conditions
Study: 12015789
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg gliclazide MR tablet under fed conditions
Study: 2201941
Drug: Intramuscular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone (4 mg/kg)
Study: 7318347
Drug: Metoprolol (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100-200 mg/day)
Study: 7318347
Drug: Pindolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5-10 mg/day)
Study: 29768070
Drug: Web-based Help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based Help Program for Drug Abuse and Depression
Study: 29768070
Drug: In-person session
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person session with addiction therapist and treatment as usual
Study: 29768070
Drug: Treatment ordinarily
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment ordinarily offered in participating treatment centers
Study: 27352487
Drug: Wheat-size moxibustion
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat-size moxibustion therapy (9 moxa cones on Zusanli (ST 36) and Feishu (BL 13) acupoints, once a day for 6 weeks)
Study: 27352487
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (follow-up visit without treatment)
Study: 27352487
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of observation group vs control group after treatment
Study: 25342209
Drug: No-treatment wait-list
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment wait-list control group
Study: 12005084
Drug: Menjugate vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menjugate vaccine
Study: 12005084
Drug: Meningitec vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningitec vaccine
Study: 12005084
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine vaccines only)
Study: 1560801
Drug: Amitriptyline (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (105 mg)
Study: 1560801
Drug: Desipramine (111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (111 mg)
Study: 2862315
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (15 mg [50 000 IU] retinol, 200 mg riboflavine, and 50 mg zinc)
Study: 18784156
Drug: Eculizumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (600 mg weekly for 4 weeks, then 900 mg at week 5 and every 14 days thereafter)
Study: 22820908
Drug: clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: clarithromycin (500 mg)
Study: 10781777
Drug: trimethoprim-sulfamethoxazole (800/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim-sulfamethoxazole (800/160 mg)
Study: 8971284
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg nitroglycerine
Study: 8971284
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg nitroglycerine
Study: 8971284
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg nitroglycerine
Study: 1345260
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg o.d.
Study: 21246067
Drug: RelyXTM Unicem
Normalized name: Hippeastrum puniceum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: RelyXTM Unicem (Ucem, self-adhesive) with no treatment
Study: 21246067
Drug: RelyXTM ARC
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RelyXTM ARC (ARC, conventional) with no treatment
Study: 19671139
Drug: escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 10 mg per day
Study: 7916004
Drug: Metoprolol (14/190
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (14/190 mg)
Study: 28823491
Drug: Weekly two‐hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly two‐hour small group sessions led by an occupational therapist for six weeks focusing on nutrition, physical activity, and self‐management strategies
Study: 25243910
Drug: Secukinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (300 mg and 150 mg)
Study: 23022106
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group 1 - NT)
Study: 19826172
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise comprising high intensity cardiovascular and resistance training, relaxation and body awareness training, massage, nine hours weekly for six weeks in addition to conventional care
Study: 18051004
Drug: 15% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% carbamide peroxide gel with potassium nitrate and fluoride (Opalescence 15% PF, OP)
Study: 11335905
Drug: Interstitial photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interstitial photodynamic therapy with rotating and reciprocating optical fibers
Study: 7890023
Drug: Physostigmine (0.0125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.0125 mg per kg body weight)
Study: 2904824
Drug: Astemizole 30
Normalized name: Astemizole
DrugBank: Astemizole (DB00637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Astemizole 30 mg taken orally once daily for 1 week
Study: 22194637
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no vaccine)
Study: 30408456
Drug: Immediate postpartum
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postpartum insertion of levonorgestrel contraceptive implants
Study: 28610898
Drug: Delayed insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed insertion of levonorgestrel contraceptive implants
Study: 25793928
Drug: Low-dose RAI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose RAI (1110 MBq)
Study: 25793928
Drug: High-dose RAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose RAI (3700 MBq)
Study: 8830061
Drug: Nefazodone, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone, 200 mg twice daily + Triazolam, 0.25 mg
Study: 8830061
Drug: Alprazolam, 1
Normalized name: Alprazolam, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam, 1 mg twice daily
Study: 8830061
Drug: Alprazolam, 1
Normalized name: Alprazolam, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam, 1 mg twice daily + Nefazodone, 200 mg
Study: 8830061
Drug: Lorazepam, 2
Normalized name: Lorazepam, 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam, 2 mg twice daily
Study: 7466726
Drug: Intrapleural BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural BCG treatment followed by scarifications (BCG-B)
Study: 28586918
Drug: Nebulized Hypertonic
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized Hypertonic Saline (HS) 3% - 4 mL, two 20-minute treatments
Study: 28586918
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline (NS) 0.9% - 4 mL, two 20-minute treatments
Study: 21736837
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil enriched with 45 μg MK-7
Study: 21736837
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil enriched with 90 μg MK-7
Study: 16766337
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral itraconazole pulse therapy for 3 months (200 mg x 2/day for 1 week/month) followed by an additional single course (200 mg/day for 7 days) after 3 months.
Study: 16766337
Drug: Modified itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Modified itraconazole pulse therapy (6-week interval) x3 followed by an additional single course (200 mg x 2/day for 7 days) after 3 months.
Study: 11738071
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (100 mg/kg)